کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
5627999 | 1579826 | 2017 | 7 صفحه PDF | دانلود رایگان |
- Depression is one of the major psychiatric comorbidity associated with epilepsy.
- Inconclusive results exist regarding safety of SSRIs for treatment of depression in epilepsy.
- These inconclusive results warrant better strategies for exploration of SSRIs for treatment of depression in epilepsy.
- There is a scientific rationale for thinking beyond SSRIs for safe and effective management of depression associated with epilepsy.
Depression is one of the major psychiatric comorbidities having a major impact on the quality of life in people with epilepsy (PWE). Selective serotonin reuptake inhibitors (SSRIs) are considered as safest therapy for the treatment of depression in PWE. Although administration of SSRIs increases the synaptic serotonin levels, it decreases the overall serotonin synthesis in the brain. Long-term therapy with SSRIs has been reported to decrease serotonin synthesis, which may be the possible reason for lessening of their antidepressant effect over time as well as elevated seizure outcomes observed in PWE. Thus the present scenario warrants streamlined studies to explore the safety and efficacy of SSRIs as well as approaches beyond SSRIs for treatment of depression in epilepsy. In this review, we outline the approaches which may restore serotonin levels rather than a pseudo enhancement of serotonin with SSRIs. The potential of various anti-inflammatory approaches such as selective cyclooxygenase-2 inhibitors, inflammatory cytokine inhibitors, and indoleamine 2,3-dioxygenase inhibitors pertaining to their serotonin restoring effects is discussed as possible therapy for treatment of depression in epilepsy.
Journal: Epilepsy & Behavior - Volume 66, January 2017, Pages 93-99